Supernus Pharmaceuticals, INC Form 4 insider transactions

Timothy C. Dec, Senior Vice President & CFO of Supernus Pharmaceuticals, reports the acquisition of stock options and restricted stock units.

Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, reports the acquisition of stock options.

Jack A. Khattar, CEO of Supernus Pharmaceuticals, reports the acquisition of 38,640 Performance Share Units.

Frank Mottola, SVP at Supernus Pharmaceuticals, was awarded 2,625 Performance Share Units on February 17, 2025, a portion of which vested upon achievement of individual performance objectives.

Frank Mottola, SVP at Supernus Pharmaceuticals, reports acquisition of performance share units.

Padmanabh P. Bhatt, Sr. VP of IP and CSO at Supernus Pharmaceuticals, exercised stock options and sold shares on February 4, 2025.

Padmanabh P. Bhatt, Sr. VP of IP and CSO at Supernus Pharmaceuticals, files an amended Form 4 to correct the number of derivative securities beneficially owned following a transaction.

Padmanabh P. Bhatt, Sr. VP of IP and CSO at Supernus Pharmaceuticals, reports the acquisition and disposal of common stock and derivative securities.

Jonathan Rubin, SVP, Chief Medical Officer of Supernus Pharmaceuticals, reports changes in beneficial ownership, including the acquisition of common stock through the Employee Stock Purchase Plan and the vesting of Performance Share Units.

Frank Mottola, SVP at Supernus Pharmaceuticals, reports acquisition of shares through employee stock purchase plan and performance share units.

Frederick M. Hudson, a director at Supernus Pharmaceuticals, exercised stock options and acquired 20,000 shares of common stock on January 22, 2025.

Jonathan Rubin, SVP and Chief Medical Officer of Supernus Pharmaceuticals, reports the acquisition and disposal of common stock related to performance share units.

Jack A. Khattar, CEO of Supernus Pharmaceuticals, reports the acquisition and disposal of company stock and performance share units on December 27, 2024.

Jack A. Khattar, CEO of Supernus Pharmaceuticals, reports the acquisition of performance share units on December 23, 2024.

Jonathan Rubin, SVP, Chief Medical Officer of Supernus Pharmaceuticals, reports the vesting of Performance Share Units based on achievement of performance objectives.

A Supernus Pharmaceuticals executive, Padmanabh P. Bhatt, exercised stock options and sold shares on December 3, 2024.

Director Charles W. Newhall III exercised stock options and sold shares of Supernus Pharmaceuticals on November 11, 2024.

Director Frederick M. Hudson sold 8,722 shares of Supernus Pharmaceuticals (SUPN) at an average price of $36.28 on November 8, 2024.

Director Georges Gemayel exercised stock options and sold shares of Supernus Pharmaceuticals on November 8, 2024.

Jack A. Khattar, CEO of Supernus Pharmaceuticals, exercised stock options and sold 125,000 shares of common stock on November 8, 2024.

Frank Mottola, SVP at Supernus Pharmaceuticals, exercised stock options and sold 15,000 shares of common stock on November 7, 2024.

Director Georges Gemayel exercised stock options and sold shares of Supernus Pharmaceuticals on November 7, 2024.

CEO Jack Khattar exercised stock options and sold shares of Supernus Pharmaceuticals on November 7, 2024.

Director Georges Gemayel reports the acquisition and disposal of Supernus Pharmaceuticals (SUPN) common stock and stock options on September 13, 2024.

Jack A. Khattar, CEO of Supernus Pharmaceuticals, reports the acquisition and disposal of company stock related to performance share units.

Jack A. Khattar, CEO of Supernus Pharmaceuticals, reports the acquisition of 21,000 performance share units.

Padmanabh P. Bhatt, a Senior VP at Supernus Pharmaceuticals, reports the acquisition and disposal of company stock related to performance share units.

Padmanabh P. Bhatt, a Senior VP at Supernus Pharmaceuticals, reports acquisition of shares through an employee stock purchase plan and vesting of performance share units.

Padmanabh P. Bhatt, Sr. VP of IP, CSO at Supernus Pharmaceuticals, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Padmanabh P. Bhatt, a Senior VP at Supernus Pharmaceuticals, exercised stock options and sold shares according to a pre-arranged trading plan.